I guess you all 3000 of u fail to address this question, so best I figure minimum wage, but knowledge of when articles hit.
ROBO why did lakewood mention you in his short thesis???????????
Funny how they held my little post back for near 2 hours.
fund in the process. Now they are likely long again, will likely write a positive SA article, Anonymous works, run opko up, they were long weeks ago, OH then short again, and write another bash. SAD but true SA can have a short term impact benefiting the author though the article can be replete with half truths.
I guess they are not going to post my small, actually long winded, rebuttal.
No this is a hedge fund, in my opinion, that has under performed, and i think they have played opko both ways, helping to run it up, they did hold a long, so, now that it up, they are trying to run it down.
Find that strange, I have written over 100 posts to SA and they stopped reviewing once I got over 25 posts, but I guess this author can pick and choose posts as it suits him. Will see if it shows up.
short the stock. Not quite sure if this is not their first SA article either, their was that anonymous author spouting the same noise. Easy enough for any fund to run a thinly traded stock up, then short it. Curious too, is this fund owned opko very recently, and then did an about face. I guess they no longer like their buy thesis.
I for one am convinced that robo is paid by someone, why else would they keep the program running day and night. I can stop by 3:00 AM and check the board to see 50 posts in last hour.
Just found that peculiar, I guess they are yahoo board readers, lol.
I took it to mean that since very few drugs go to phase three in Germany that the hospitals are trying to get approval for reimbursement now because the hospitals anticipate approval. I have no idea how long the approval process is, BUT NOTE, to pass phase 3, they need have results INFERIOR to the completed phase 1-2, DO not miss that point. They need only show 6 months extended survival, a slam dunk.
Unlike most ceo's, the most telling line was our financial position is vastly improved, and dilution is our last choice, the insiders, myself included, " have a lot of skin in the game. "
will take a little time to relisten, but, she presented info in a straight forward informed manner. I was impressed, AND I usually thing these presenters are lousy.
Yes, my point is really that both Lab Corp, and Quest have thousands upon thousands of tests they can run, and they acquire licenses for more on a daily basis or as they are invented. Opko needs only their piece of the pie, their own 8-10 tests, Lab Corp and Quest will not really miss the revenue, but it could be huge for OPKO. Opko just needs the 8-10 most common tests, let those guys keep the rest, opko will not need more than 8-10 tests to make Claros big. Just developing any one test takes years, it might be where OPKO licenses a few from them.
Both quest and lab corp will be around for years, in fact OPKO has a deal with one of those two, forget which one, for them to work on the Alzheimer's test. All opko needs is to carve out it's niche market, focus on urology, then move on to another area once it is firmly established. This will take time, but they are building the infrastructure. I for one would like to see them lower the price on 4k, and go after the psa market, but that is me. Opko wants a POC psa test, and a POC 4k. I guess if the POC system is in every office it will provide two sources of revenue.
South America, Russia and neighbors, Europe, Israel, US. The fact our 4k is now being tested in so many states, through the largest urology practices will create an instant market upon launch. The fact Rayaldy is the ONLY drug that meets FDA guidelines for Vit D insufficiency means largest market share. It is a matter of time but both will be great products in a year or two.